Recent posts

TypePostAuthorRepliesLast updated
Blog entryColombia Issues Public Interest Declaration To Lower Price of Glivec KEI Staff03 days 9 hours ago
Blog entryHuman Rights Council heats up during informal talks on the primacy of human rights over international trade and IP regimes thiru03 days 9 hours ago
Blog entryS. Ward Casscells, Pentagon Medical Chief, Praised Army Role in Xtandi Development Zack Struver05 days 5 hours ago
Blog entryNIH to taxpayers — we don't care about high prices in US for Xtandi. KEI Staff05 days 15 hours ago
PageNews reports on Senator Hatch pressure over Colombia compulsory license on Novartis drug James Love06 days 16 hours ago
PageBackground FAQ on Glivec (imatinib) compulsory license in Colombia Zack Struver01 week 2 days ago
Blog entryUS Chamber of Commerce defends Swiss drug company charging excessive prices in Colombia James Love01 week 5 days ago
Blog entryNovartis complaints over public interest declaration debunked Andrew Goldman01 week 5 days ago
Blog entryWIPO IGC30: Questions remain on protection of genetic resources as hard decisions postponed until 2017 Staff01 week 5 days ago
Blog entryWHA69: Resolution WHA69.23 on CEWG follow-up charts course for WHO's work on R&D thiru01 week 5 days ago
Book pagePrizes to stimulate innovation James Love01 week 6 days ago
Blog entryObama administration blocking consensus at Human Rights Council on access to medicines resolution thiru02 weeks 11 hours ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc. Diane Singhroy02 weeks 3 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to IntelliPanel Medical, LLC Diane Singhroy02 weeks 3 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation Diane Singhroy02 weeks 3 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc. Diane Singhroy02 weeks 3 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation Diane Singhroy02 weeks 3 days ago
Blog entryAlfred Engelberg and Aaron Kesselheim in Nature on Bayh-Dole royalty free rights in patents, Xtandi case James Love02 weeks 3 days ago
Blog entryColombia Ministry of Health Announces that Negotiations With Novartis Have Failed; Declaration of Public Interest Imminent Andrew Goldman02 weeks 4 days ago
Blog entryXtandi patient on Medicare — with supplement — pays $441.97 per month Zack Struver02 weeks 4 days ago
Blog entryUS proposal to seek a "better understanding" of Switzerland's implementation of the Nagoya Protocol receives chilly reception thiru02 weeks 5 days ago
Blog entryWIPO IGC30: Narrowing existing gaps relating to the protection of genetic resources? Staff02 weeks 6 days ago
Blog entryWIPO IGC30: Clean and track-changed version of Facilitators' text on Intellectual Property and Genetic Resources thiru02 weeks 6 days ago
PageWIPO IGC30 thiru02 weeks 6 days ago
Book pageAnne-Beatrix Keller Semadeni, Director of Development James Love03 weeks 5 days ago